Urinary incontinence and overactive bladder disorders are estimated to affect more than 10% of the female population. However, presentation, diagnosis and treatments rates are poor. In the US, the employment of Continence Nurses provides an ideal opportunity to ensure that patients are able to gain access to expert advice and treatment.
Scope
Assessment of the responsibilities of the US Continence Nurse including their role in the referral pathway, diagnosis and prescribing of drug therapy
Evaluation of reasons influencing patient presentation including educational and marketing campaigns
Analysis of treatment methods employed, influences on treatment choice and perception of current drug therapies
Identification of unmet needs and potential drivers of change
Report Highlights Continence Nurses in the US play a varied role in the management of urinary incontinence and overactive bladder patients, with over two thirds recommending or prescribing pharmacological therapies. Pharmaceutical companies promoting pharmacological therapies in the US should consider Continence Nurses as key targets.
For more than 50% of patients presenting to Continence Nurses, this is the first healthcare professional that the patient will have spoken to about their condition; frequently identified as a direct result of presenting for another condition. Therefore, Continence Nurses are vital to the diagnosis and referral of this subgroup of patients.
Continence Nurses are likely to have more time than other physicians to discuss the nature of symptoms and side effects with patients. By supporting Continence Nurses, pharmaceutical companies could improve patients' knowledge of the condition and its treatment, thereby improving treatment retention and switching rates.
Reasons to Purchase
Understand the role of Continence Nurses in the treatment of urinary incontinence and overactive bladder for strategic product planning and targeting
Evaluate methods for improving presentation rates and thereby utilization of treatments for urinary incontinence and overactive bladder disorders
Identify concerns of Continence Nurses and patients regarding current treatment and unmet needs
Table of Contents
ABOUT DATAMONITOR HEALTHCARE - page 2
About the CNS pharmaceutical analysis team - page 2
OVERVIEW - page 5
This product has been designed for delivery in a slide pack format (PowerPoint). - page 5
Please select the slide pack option from the download menu at the side of the page - page 5
Introduction - page 5
Scope of this report - page 5
Research and analysis highlights - page 6
Key reasons to read this report - page 6
APPENDIX A - page 7
Research methodology - page 7
Continence nurse questionnaire - page 7
Screening Information - page 7
Overview of the study - page 9
Section One Epidemiology - page 10
Section Two Presentation and help seeking behavior - page 11
Section Three Diagnosis and management - page 16
Referral pattern - page 17
Section Four Treatment - page 20
Non-pharmacological treatment - page 22
Pharmacological treatment - page 23
Section Five General - page 24
Section A: Drug influences - page 24
Section B: The general treatment of urinary incontinence and overactive bladder - page 26
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.
